MarketPeel
Insider Trading Intelligence
SL

Sue-jean Lin

ARQT
DIRECTOR · ARCUTIS BIOTHERAPEUTICS, INC. · CIK 0001867788
FILING MIX · LIFETIME78%/22%
BUYS
14
SELLS
4
TOTAL VALUE
$1.11M
COMPANIES
2
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
34,542
AVG SELL PX
$29.74
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Sue-jean Lin, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-1.27%+1.73%-2.99%-2.99%
14d1+0.00%+0.88%+2.23%-1.35%-1.35%
30d1+100.00%-4.26%+3.24%-7.50%-7.50%
60d1+100.00%-14.82%+3.07%-17.89%-17.89%
90d1+100.00%-14.47%+2.04%-16.51%-16.51%
180d1+100.00%-31.70%
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ARQT · 27,567 shares · as of Jun 15, 2026
013,00226,00439,00552,00720222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 14 buys / 4 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,946$24.38$120.6K27,567Jun 15, 2026Jun 17, 2026View →
STVN
STEVANATO GROUP S.P.A.
PURCHASEGRANT
Stock grant
4,9756,975Jun 12, 2026Jun 26, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,77832,513Jun 5, 2026Jun 9, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,66716,667Jun 5, 2026Jun 9, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
25,272$30.78$778.0K26,735Nov 24, 2025Nov 25, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
7,2205,000Nov 24, 2025Nov 25, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
18,0529,000Nov 24, 2025Nov 25, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
7,220$7.51$54.2K52,007Nov 24, 2025Nov 25, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
18,052$8.63$155.8K44,787Nov 24, 2025Nov 25, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,60926,735Jun 12, 2025Jun 16, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,56820,568Jun 12, 2025Jun 16, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,05227,052Jun 14, 2024Jun 18, 2024View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,13919,126Jun 14, 2024Jun 18, 2024View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,3758,987May 31, 2023Jun 2, 2023View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,22012,220May 31, 2023Jun 2, 2023View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,79611,796Jun 1, 2022Jun 3, 2022View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,3124,612Jun 1, 2022Jun 3, 2022View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,72325,723Jun 9, 2021Jun 16, 2021View →
Other insiders · ARQT
Loading peer insiders…
About this filer
CIK 0001867788
ROLE
Director
PRIMARY
ARQT
COMPANIES
2
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001867788DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback